ATE127691T1 - Verwendung von vitamin-d-analoga zur behandlung von akne. - Google Patents

Verwendung von vitamin-d-analoga zur behandlung von akne.

Info

Publication number
ATE127691T1
ATE127691T1 AT91905594T AT91905594T ATE127691T1 AT E127691 T1 ATE127691 T1 AT E127691T1 AT 91905594 T AT91905594 T AT 91905594T AT 91905594 T AT91905594 T AT 91905594T AT E127691 T1 ATE127691 T1 AT E127691T1
Authority
AT
Austria
Prior art keywords
pct
vitamin
analogue
preparation
sec
Prior art date
Application number
AT91905594T
Other languages
English (en)
Inventor
Wagn Ole Godtfredsen
Original Assignee
Leo Pharm Prod Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharm Prod Ltd filed Critical Leo Pharm Prod Ltd
Application granted granted Critical
Publication of ATE127691T1 publication Critical patent/ATE127691T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
AT91905594T 1990-03-01 1991-02-25 Verwendung von vitamin-d-analoga zur behandlung von akne. ATE127691T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909004544A GB9004544D0 (en) 1990-03-01 1990-03-01 Novel treatment ii

Publications (1)

Publication Number Publication Date
ATE127691T1 true ATE127691T1 (de) 1995-09-15

Family

ID=10671792

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91905594T ATE127691T1 (de) 1990-03-01 1991-02-25 Verwendung von vitamin-d-analoga zur behandlung von akne.

Country Status (11)

Country Link
US (1) US5292727A (de)
EP (1) EP0517797B1 (de)
JP (1) JPH05504959A (de)
AT (1) ATE127691T1 (de)
AU (1) AU7458891A (de)
DE (1) DE69113029T2 (de)
DK (1) DK0517797T3 (de)
ES (1) ES2079063T3 (de)
GB (1) GB9004544D0 (de)
GR (1) GR3017413T3 (de)
WO (1) WO1991012807A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362719A (en) * 1990-03-01 1994-11-08 Leo Pharmaceutical Products, Ltd. A/S Lovens Kemiske Fabrik Produktionsaktieselskab) Use of vitamin-D analogues in the treatment of acne
USRE39706E1 (en) * 1993-01-15 2007-06-26 Leo Pharma A/S Crystalline form of a vitamin D analogue
US5384314B1 (en) * 1994-03-11 1997-08-05 Hoffmann La Roche 1alpha-fluoro-25-hydroxy-16-ene-23-yne-cholecalciferol
PE28297A1 (es) * 1995-01-26 1997-08-20 Hoffmann La Roche Empleo dermatologico de derivados de vitamina d
EP1051974A4 (de) * 1997-12-09 2001-09-12 Chugai Pharmaceutical Co Ltd Vitamin-d3-derivate enthaltende lotionen
US6432422B1 (en) * 1997-12-09 2002-08-13 Chugai Seiyaku Kabushiki Kaisha Creams containing vitamin D3 derivatives
US6491936B1 (en) 1997-12-09 2002-12-10 Chugai Seiyaku Kabushiki Kaisha Creams containing vitamin D3 derivatives
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
ES2671785T3 (es) * 1999-04-23 2018-06-08 Leo Pharma A/S Composición farmacéutica para uso dérmico para el tratamiento de la psoriasis que comprende vitamina D y un corticosteroide
WO2001015702A1 (fr) 1999-08-31 2001-03-08 Chugai Seiyaku Kabushiki Kaisha Capsules molles
KR100611544B1 (ko) * 2000-08-30 2006-08-10 쥬가이 세이야쿠 가부시키가이샤 오씨티 제제
EP1458678A1 (de) * 2002-11-18 2004-09-22 Teva Pharmaceutical Industries Limited Kristallisationsverfahren zur reinigung von calcipotriene
GB0307865D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US7205006B2 (en) * 2003-09-25 2007-04-17 Prime Pharmaceutical Corporation Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
FR2871696B1 (fr) * 2004-06-17 2006-11-10 Galderma Sa Composition topique pour le traitement du psoriasis
CA2588396C (en) * 2004-11-22 2013-04-23 Wisconsin Alumni Research Foundation 17,20(e)-dehydro vitamin d analogs and their uses
ES2407407T3 (es) 2005-06-01 2013-06-12 Glaxosmithkline Intellectual Property Development Limited Formulación de vitamina
WO2006138056A1 (en) * 2005-06-15 2006-12-28 Apollo Pharmaceutical, Inc. Pharmaceutical composition comprising a mahonia aquifolium extract for the treatment of psoriasis
EP3095447B1 (de) 2006-02-03 2021-11-24 OPKO Renal, LLC Behandlung von vitamin-d-insuffizienz und -mangel mit 25-hydroxyvitamin d2 und 25-hydroxyvitamin d3
PT2037936E (pt) 2006-06-21 2014-09-04 Opko Renal Llc Método de tratamento e prevenção do hiperparatiroidismo secundário
CN101505725A (zh) * 2006-08-29 2009-08-12 特瓦制药工业有限公司 包含含维生素D的化合物和皮质类固醇化合物的具有低pH相容性的稳定的药理学活性组合物
US20100273748A1 (en) * 2006-09-08 2010-10-28 The Regents Of The University Of California Antimicrobial therapy
US20100056644A1 (en) * 2006-11-29 2010-03-04 Nilendu Sen Pharmaceutical compositions containing anhydrous calcipotriene
CN104523707B (zh) 2007-04-25 2022-08-26 欧普科Ip 控股Ii 有限公司 包含维生素d化合物和蜡质载体的口服控释组合物
WO2008134518A2 (en) 2007-04-25 2008-11-06 Cytochroma Inc. Methods and compounds for vitamin d therapy
US20100144684A1 (en) 2007-04-25 2010-06-10 Proventiv Therapeutics, Inc. Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
US7727562B2 (en) * 2007-06-21 2010-06-01 Blackman Steven T Liquid compositions containing solubilized benzoyl peroxide
KR101685031B1 (ko) 2008-04-02 2016-12-09 사이토크로마 인코포레이티드 비타민 ｄ 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
JP5652723B2 (ja) * 2012-08-17 2015-01-14 フォーモサ・ラボラトリーズ・インコーポレーテッド マキサカルシトールの新しい結晶形態
JP2014144929A (ja) * 2013-01-29 2014-08-14 Daiichi Sankyo Healthcare Co Ltd ビタミン類を含有するニキビの予防又は治療用組成物
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CR20170085A (es) 2014-08-07 2017-04-25 Opko Ireland Global Holdings Ltd Terapia adjuntiva con 25-hidroxi vitamina d
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610978A (en) * 1983-03-22 1986-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same
WO1986005395A1 (en) * 1985-03-14 1986-09-25 Chugai Seiyaku Kabushiki Kaisha Composition for treating skin disease
US5145846A (en) * 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
EP0398217B1 (de) * 1989-05-18 1994-01-12 F. Hoffmann-La Roche Ag Dehydrocholecalciferolderivate

Also Published As

Publication number Publication date
DE69113029D1 (de) 1995-10-19
DE69113029T2 (de) 1996-03-07
EP0517797A1 (de) 1992-12-16
GR3017413T3 (en) 1995-12-31
WO1991012807A1 (en) 1991-09-05
JPH05504959A (ja) 1993-07-29
GB9004544D0 (en) 1990-04-25
US5292727A (en) 1994-03-08
ES2079063T3 (es) 1996-01-01
AU7458891A (en) 1991-09-18
DK0517797T3 (da) 1995-11-13
EP0517797B1 (de) 1995-09-13

Similar Documents

Publication Publication Date Title
ATE127691T1 (de) Verwendung von vitamin-d-analoga zur behandlung von akne.
BR9814984A (pt) Processos para tratar condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio em uma paciente pós-menopáusica e para reduzir o risco de fraturas ósseas osteoporóticas em uma paciente, e, conjunto para uso por uma comsumidora atormentada com, ou suscetìvel a, condições fìsicas resultantes do declìnio pós-menopáusico de estrogênio
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
AU2003217055A1 (en) Protein for use in hypoxia related conditions
ES2126122T3 (es) Nitrato-aminoacido-disulfuros para la terapia de enfermedades del sistema cardio-circulatorio.
NZ314839A (en) 1,25-Dihydroxy-16,23Z-diene-20-epi-16-ene-cholecalciferol (Vitamin D3) analogues
DE69428791T2 (de) Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden
MX9306960A (es) Composiciones de extracto de corteza de roble, compositiones sinteticasrelacionadas, y metodo para su utilizacion.
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
EP0401903A3 (de) Verwendung von Vanilloiden zur Behandlung von Erkrankungen der Atemwege
DE3587956D1 (de) Ausrüstung für die Verwendung bei der Behandlung von Osteoporose.
DK1632248T3 (da) Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed
NZ326345A (en) Composition containing diosgenin
DE69326122D1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
ES2153689T3 (es) Pastilla de jabon antiseptico.
NO955347D0 (no) Hormonelt middel for terapi av akne samt anvendelse derav
DE69424679T2 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
BR9708511A (pt) Utilização de compostos utilização de ácido 6-[3-(1-adamantil)-4-metoxifenil]-2naftóico e utilização do ácido 6-[3-(1-adamantil)-4-hidroxifenil]-2-naftóico
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69109293T2 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.
ATE87482T1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
DE69801907D1 (de) Verwendung von 9,10-secocholesta-5,7,10(19)-trien-1,3-ol (alfacalcidol)